BioLargo, Inc. Overview
Pro stress-test →BioLargo is a cleantech and life sciences innovator that develops and commercializes platform technologies addressing critical environmental challenges including PFAS water contamination, advanced water and wastewater treatment, industrial odor and VOC control, and infection control. The company operates through five subsidiaries across multiple US states and Canada, combining environmental remediation expertise with medical-grade solutions.
Strategic Profile
Pro stress-test →BioLargo differentiates through proprietary technologies like its Aqueous Electrostatic Concentrator (AEC) for PFAS treatment and Clyrasept™ for advanced wound care. The company is transitioning toward commercialization and revenue generation, with recent municipal water system installations and clinical validation of medical products positioning it at the intersection of environmental and life sciences innovation.
Competitive Landscape
Pro stress-test →BioLargo competes in fragmented environmental remediation and advanced water treatment markets against larger incumbents like Aquatech International, H2O Innovation, and ChemTreat, plus smaller specialized players. Its proprietary technology and integrated medical-environmental approach provide differentiation, though scale and capitalization disadvantages versus established competitors remain significant.
Industry Context
BioLargo, Inc. operates in Environmental Remediation & CleanTech / Advanced Medical Technologies.
Key facts
Headquarters: Westminster, California, US · Revenue: $17.8M · Market cap: $73.7M